Product Name: Furosemide Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name: Hospira, Inc.
And Address: 275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone:
CHEMTREC: 800 424-9300
Hospira, Inc.: 224 212-2055

Product Name: Furosemide Injection, USP
Synonyms: None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name: Furosemide
Chemical Formula: C_{12}H_{11}ClN_{2}O_{5}S

<table>
<thead>
<tr>
<th>Component</th>
<th>Approximate Percent by Weight</th>
<th>CAS Number</th>
<th>RTECS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>1</td>
<td>54-31-9</td>
<td>CB2625000</td>
</tr>
<tr>
<td>Water</td>
<td>99</td>
<td>7732-18-5</td>
<td>ZC0110000</td>
</tr>
</tbody>
</table>

3. HAZARD INFORMATION

Emergency Overview: In clinical use, this material is used to promote urination. Possible target organs include the kidneys, fetus, DNA and ears.

Occupational Exposure Potential: Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms: No signs or symptoms from occupational exposure are known. Clinical data suggest the following: electrolyte imbalances, dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain, muscle weakness, decreased blood pressure, fast heart rate, nausea, vomiting, ringing in the ear, dizziness, headaches.

Medical Conditions Aggravated by Exposure: Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: kidney, ears, liver.
Product Name: Furosemide Injection, USP

4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable

Fire & Explosion Hazard: None

Extinguishing Media: Use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures: No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal: Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling: Protect from light by retaining in carton until contents have been used.

Storage: No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).

Special Precautions: Protect from freezing, light and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Component</th>
<th>OSHA-PEL</th>
<th>ACGIH-TLV</th>
<th>Hospira EEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>8 hr TWA: Not Established</td>
<td>8 hr TWA: Not Established</td>
<td>8 hr TWA: 100 mcg/m³ STEL: Not Established</td>
</tr>
</tbody>
</table>

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.
Product Name: Furosemide Injection, USP

Respiratory Protection  Respiratory protection is not needed during normal product use.

Skin Protection  If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.

Eye Protection  Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.

Engineering Controls  Engineering controls are not needed during normal product use conditions.

<table>
<thead>
<tr>
<th>9. PHYSICAL/CHEMICAL PROPERTIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance/Physical State</td>
</tr>
<tr>
<td>Odor</td>
</tr>
<tr>
<td>Boiling Point</td>
</tr>
<tr>
<td>Freezing Point</td>
</tr>
<tr>
<td>Vapor Pressure</td>
</tr>
<tr>
<td>Vapor Density (Air=1)</td>
</tr>
<tr>
<td>Evaporation Rate</td>
</tr>
<tr>
<td>Bulk Density</td>
</tr>
<tr>
<td>Specific Gravity</td>
</tr>
<tr>
<td>Solubility</td>
</tr>
<tr>
<td>pH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10. STABILITY AND REACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Stability</td>
</tr>
<tr>
<td>Incompatibilities</td>
</tr>
<tr>
<td>Hazardous Products</td>
</tr>
<tr>
<td>Hazardous</td>
</tr>
<tr>
<td>Polymerization</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11. TOXICOLOGICAL INFORMATION:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Toxicity – Oral:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient(s)</th>
<th>Percent</th>
<th>Test Type</th>
<th>Value</th>
<th>Units</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>100</td>
<td>LD50</td>
<td>800-4600</td>
<td>mg/kg</td>
<td>Rabbits, Dogs, Mice, Rats</td>
</tr>
</tbody>
</table>

LD50 is the dosage producing 50% mortality.
Product contains approximately 1% Furosemide.

Mutagenicity  Positive in the mouse lymphoma and chromosomal aberration assays.
Target Organ Effects  In clinical use target organ effects include kidney, fetus, ears, DNA.

<table>
<thead>
<tr>
<th>12. ECOLOGICAL INFORMATION:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aquatic Toxicity</td>
</tr>
</tbody>
</table>


Product Name: Furosemide Injection, USP

13. DISPOSAL CONSIDERATIONS:

Waste Disposal
Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal
Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT
Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status
Not Regulated

CERCLA Status
Not Regulated

SARA Status
Not Regulated

RCRA Status
Not Regulated

PROP 65 (Calif.)
Not Regulated

Notes:
TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator
Global Occupational Toxicology

Date Prepared
September 15, 2005

Date Revised
October 21, 2008

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.